Treatment failure is still a problem for many individuals with HIV. In Europe alone, over 10,000 individuals with HIV are classed as "heavily treatment experienced"1 – but what does this really mean?
Professor Chloe Orkin and her colleagues Pedro Cahn, Antonella Castagna, Brinda Emu, Richard Harrigan, Dan Kuritzkes, Mark Nelson and Jonathan Schapiro met in December 2020 and again in 2021. Their discussions have been published in HIV Medicine (access the article below) and identify the unmet needs of individuals with HIV who are in need of further treatment options, broaden the definition of heavily treatment experienced people, and clarify the use of newer agents, with an emphasis on the utilization of entry inhibitors in this population.
This programme has been submitted for accreditation to the European Union of Medical Specialists (UEMS). User engagement with the site is being tracked, IMP will contact users with further details regarding accreditation.
Identify individuals with HIV who have limited treatment options and describe their needs
Describe the different mechanisms of action of existing and novel entry inhibitors
Understand the impact different HIV entry inhibitors have on immune recovery
Describe and manage toxicities associated with HIV entry inhibitors
